System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Manoj Pandey is an expert in Immunology at Banaras Hindu University (India). As of October 2026, ScienceLeadR ranks Manoj Pandey in the top 1% of experts worldwide for Mouth Neoplasms and Gallbladder Diseases, and in the top 1% of experts in India for Carcinoma. Manoj Pandey has authored 83 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 1 of them ongoing. SLR score: 731 (community average: 125). How the SLR is computed.

LeadR Profile

Manoj Pandey Banaras Hindu University India
731 ScienceLeadR Reputation 731

Unlock

Register Login
Network Map

Immunology

Subspecialties: Oncology - Surgery - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Banaras Hindu University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 83

Citations

Citations: 131 1st author: 22 Last author: 33 Unique author: 6

Main journals

J Immunol 7
World J Surg Oncol 7
Research Square (Research Square) 4
J Gastroenterol Hepatol 3
Crit Rev Oncol Hematol 2

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Risk-stratified management of the clinically node-negative neck in early-stage oral squamous cell carcinoma: Elective neck dissection versus watch-and-wait with therapeutic dissection.
PMID 42585846 — cells, oral stage, neck dissection, carcinoma, squamous cell, morbidity, therapeutics, medical oncology, dissection		Eur J Surg Oncol20260
Interfacial Amine Engineering Unlocks Enhanced MRI Relaxivity in Silica-Coated Hematite Nanoparticles.
PMID 42689625 — contrast media, amines, nanoparticles, therapeutics		Anal Chem20260
Hypoxia-regulated non-coding RNAs in OSCC liquid biopsy: from molecular mechanisms to AI-driven precision oncology.
PMID 42677123 — cells, microscopy, electron, scanning transmission, neoplasms, multiple chronic conditions, rna, circular, biopsy, biomarkers, exosomes, hypoxia, artificial intelligence, liquid biopsy		Front Oncol20260
Integrative transcriptomic analysis identifies shared coding and non-coding biomarkers in tongue squamous cell carcinoma across diverse populations.
PMID 42658318 — cells, genes, tongue, carcinoma, squamous cell, neoplasms, biomarkers		Discov Oncol20260
From Association to Causation: Advancing the Biliary Multi-Omics Paradigm in Gallbladder Carcinogenesis: A Response.
PMID 42563440 — liver diseases, gastroenterology, gallbladder, multiple chronic conditions, carcinogenesis		J Gastroenterol Hepatol20261

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Director: 1

By phase:

N/A 7
Phase 2/Phase 3 2
Phase 3 1

By status:

Completed 6
Recruiting 3
Unknown 1

By type:

Interventional 5
Observational 5

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
NCT05833815 — gallbladder, neoplasms, drug therapy, everolimus, biliary tract, gallbladder neoplasms, chemotherapy, carcinoma		Phase 2/Phase 3Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS